Psoriatic arthritis Trials in Sofia, Bulgaria
Conditions / Psoriatic arthritis / Sofia, Bulgaria
Clinical trials for Psoriatic arthritis investigate a range of treatment strategies and patient populations.
28 total trials for this combination
Showing top 10 of 28 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06671483 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | RECRUITING | PHASE3 |
| NCT04908202 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs | ACTIVE_NOT_RECRUITING | — |
| NCT04908202 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs | ACTIVE_NOT_RECRUITING | — |
| NCT03675308 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03926195 | Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis | COMPLETED | PHASE2 |
| NCT04908202 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs | ACTIVE_NOT_RECRUITING | — |
| NCT02029495 | Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis | TERMINATED | PHASE3 |
| NCT02376790 | Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT03104400 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | COMPLETED | PHASE3 |
| NCT02605642 | Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade | COMPLETED | — |